HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Kemp H. Kernstine Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kernstine, K. H. Search for Related Content PubMed PubMed Citation Articles by Kernstine, K. H. Related Collections Lung - cancer

J Thorac Cardiovasc Surg 2003;126:1700-1703
© 2003 The American Association for Thoracic Surgery

Editorial

Positron emission tomography with 2-[¹⁸F]fluoro-2-deoxy-D-glucose: can it be used to accurately stage the mediastinum in non–small cell lung cancer as an alternative to mediastinoscopy?

^a Division of Cardiothoracic Surgery, The University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA

Received for publication April 16, 2003; accepted for publication April 21, 2003.

^* Address for reprints: Kemp H. Kernstine, MD, PhD, The University of Iowa Hospitals, Division of Cardiothoracic Surgery, 200 Hawkins Dr, 1616B-JCP, Iowa City, IA 52242, USA
Kemp-kernstine@uiowa.edu

The first 300 words of the full text of this article appear below.

Last year national health care costs rose 10%. Health care providers and third-party payers are under increasing pressure to reduce costs yet maintain or even improve quality. So can adding an additional test, such as positron emission tomography (PET), to an already expensive evaluation, such as lung cancer assessment, reduce cost and improve quality? It could, if it reduces unnecessary tests and surgery and accurately directs treatment.

Simply, PET is expensive. The high quality, 3-dimensional reconstruction capability, in-computer software systems cost $1.5 to $2.0 million; computed tomography combined systems PET/CT are more than $2.0 million (Sue Ann Halliday, ImageMed Group, LLC, and Barry Siegel, Washington University, St Louis, Mo, personal communications). To provide appropriate space in most medical centers costs an additional $1.5 to $2.0 million. The radiopharmaceutical contrast is also expensive. For the study of lung cancer, most centers use fluorodeoxyglucose F 18 (FDG). It has a brief shelf life, the half-life being 110 minutes. For in-house production, a cyclotron is used that costs $1.0 to $2.0 million. A practical alternative, purchase of commercially made FDG, is approximately $300 to $450 per dose. Thus the initial cost for a complete in-house system is $4 to $6 million dollars. This total does not include the costs of the technicians, part- or full-time physicists, nurses, and nuclear radiologists appropriately trained to run, operate, and maintain the equipment and to read the resultant images. The per-study cost for an ear lobes to pelvis single-patient study in most medical centers is $2800 to $3500, nearly 7 times the cost of a chest/upper abdominal computed tomogram.

The use of PET and the conclusions we make are dependent on two assumptions. First, staging matters. Identifying the state of biologic progression or stage to determine the prognosis and management is important to success in treatment. Second, . . . [Full Text of this Article]

This article has been cited by other articles:

				P. Macchiarini, M. Altmayer, T. Go, T. Walles, K. Schulze, I. Wildfang, A. Haverich, M. Hardin, and Hannover Interdisciplinary Intrathoracic Tumor Tas Technical Innovations of Carinal Resection for Nonsmall-Cell Lung Cancer Ann. Thorac. Surg., December 1, 2006; 82(6): 1989 - 1997. [Abstract] [Full Text] [PDF]

				C. Schimmer, K. Neukam, and O. Elert Staging of non-small cell lung cancer: clinical value of positron emission tomography and mediastinoscopy Interactive CardioVascular and Thoracic Surgery, August 1, 2006; 5(4): 418 - 423. [Abstract] [Full Text] [PDF]

				G. J.M. Herder, H. Kramer, O. S. Hoekstra, E. F. Smit, J. Pruim, H. van Tinteren, E. F. Comans, P. Verboom, C. A. Uyl-de Groot, A. Welling, et al. Traditional Versus Up-Front [18F] Fluorodeoxyglucose-Positron Emission Tomography Staging of Non-Small-Cell Lung Cancer: A Dutch Cooperative Randomized Study J. Clin. Oncol., April 20, 2006; 24(12): 1800 - 1806. [Abstract] [Full Text] [PDF]

				J. Kuzdzal, M. Zielinski, B. Papla, A. Szlubowski, L. Hauer, T. Nabialek, W. Sosnicki, and J. Pankowski Transcervical extended mediastinal lymphadenectomy--the new operative technique and early results in lung cancer staging Eur. J. Cardiothorac. Surg., March 1, 2005; 27(3): 384 - 390. [Abstract] [Full Text] [PDF]